ArticleAssay and drug development technologies
Systematically Prioritizing Candidates in Genome-Based Drug Repurposing.
Article in Assay and drug development technologies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The landscape of the methodology in drug repurposing using human genomic data: a systematic review.Briefings in bioinformatics · 2024Pooled it
- Enhanced pain relief with guanfacine as an adjuvant for trigeminal nerve blocks: insights from a PheWAS-guided randomized controlled study.Pain medicine (Malden, Mass.) · 2025Trial
- Recombinant Platelet-Derived Growth Factor in Tissue Repair: A Review Exploring Frontiers in Regenerative Medicine.Plastic and reconstructive surgery · 2026Review
- Guanfacine as a potential preventive therapy for chronic migraine: a mechanistic hypothesis.Frontiers in neurology · 2026Article
- Statins for polycystic ovary syndrome in varying resource settings: a phenome-wide association study and evidence synthesis.Frontiers in pharmacology · 2025Article
- From Lab to Clinic: Success Stories of Repurposed Drugs in Treating Major Diseases.Advances in pharmacological and pharmaceutical sciences · 2025Review
- Repurposing N-acetylcysteine for management of non-acetaminophen induced acute liver failure: an evidence scan from a global health perspective.Translational gastroenterology and hepatology · 2024Article
- An update on the global treatment of invasive fungal infections.Future microbiology · 2023Review
- Computational drug repurposing based on electronic health records: a scoping review.NPJ digital medicine · 2022Article
- Virtual Screening for the Discovery of Microbiome β-Glucuronidase Inhibitors to Alleviate Cancer Drug Toxicity.Journal of chemical information and modeling · 2022Article
- The grand challenge of discovering new cardiovascular drugs.Frontiers in drug discovery · 2022Article
- Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance.Frontiers in immunology · 2022Review
- Medication history-wide association studies for pharmacovigilance of pregnant patients.Communications medicine · 2022Article
- Identification and Development of Therapeutics for COVID-19.mSystems · 2021Article
- Article
- Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases.Frontiers in genetics · 2021Article
- The Musculoskeletal Knowledge Portal: Making Omics Data Useful to the Broader Scientific Community.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Drug repurposing is the application of approved drugs to treat diseases separate and distinct from their original indications. Herein, we define the scope of all practical precision drug repurposing using DrugBank, a publicly available database of pharmacological agents, and BioVU, a large, de-identified DNA repository linked to longitudinal electronic health records at Vanderbilt University Medical Center. We present a method of repurposing candidate prioritization through integration of pharmacodynamic and marketing variables from DrugBank with quality control thresholds for genomic data derived from the DNA samples within BioVU. Through the synergy of delineated "target-action pairs," along with target genomics, we identify ∼230 "pairs" that represent all practical opportunities for genomic drug repurposing. From this analysis, we present a pipeline of 14 repurposing candidates across 7 disease areas that link to our repurposability platform and present high potential for randomized controlled trial startup in upcoming months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.